GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CStone Pharmaceuticals (STU:PH4) » Definitions » COGS-to-Revenue

CStone Pharmaceuticals (STU:PH4) COGS-to-Revenue : 0.41 (As of Jun. 2023)


View and export this data going back to 2019. Start your Free Trial

What is CStone Pharmaceuticals COGS-to-Revenue?

CStone Pharmaceuticals's Cost of Goods Sold for the six months ended in Jun. 2023 was €13.92 Mil. Its Revenue for the six months ended in Jun. 2023 was €33.70 Mil.

CStone Pharmaceuticals's COGS to Revenue for the six months ended in Jun. 2023 was 0.41.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. CStone Pharmaceuticals's Gross Margin % for the six months ended in Jun. 2023 was 58.68%.


CStone Pharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for CStone Pharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CStone Pharmaceuticals COGS-to-Revenue Chart

CStone Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial - 0.23 0.44 0.42 0.34

CStone Pharmaceuticals Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 0.35 0.50 0.41 -

CStone Pharmaceuticals COGS-to-Revenue Calculation

CStone Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=20.49 / 59.57
=0.34

CStone Pharmaceuticals's COGS to Revenue for the quarter that ended in Jun. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=13.924 / 33.7
=0.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CStone Pharmaceuticals  (STU:PH4) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

CStone Pharmaceuticals's Gross Margin % for the six months ended in Jun. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 13.924 / 33.7
=58.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


CStone Pharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of CStone Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


CStone Pharmaceuticals (STU:PH4) Business Description

Traded in Other Exchanges
Address
218 Xinghu Street, C1 Building, North Block, Suzhou Industrial Park, Shanghai, CHN, 215123
CStone Pharmaceuticals is engaged in the development and commercialization of innovative tumor immunotherapy and molecular-targeted drugs. It has been operating in one reportable segment, the research and development of complex biopharmaceutical products.

CStone Pharmaceuticals (STU:PH4) Headlines

No Headlines